You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥(01093.HK)午後升幅擴至11%逼近52周高位交投活躍
阿思達克 05-14 14:28
石藥集團(01093.HK)繼昨天升至10.24元創逾八個月高位遇壓隨大市倒跌後,今天股價再探頂,尤其是午後升幅擴大,最高見11.08元,接近去年8月尾所創逾52周高位11.16元,現造10.96元,急漲11%,為最強藍籌;成交急增至1.27億股,創兩個月高,涉資13.48億元。

石藥日前公布,附屬石藥集團歐意開發的糖尿病藥「苯甲酸阿格列汀片(25mg)」及抗腫瘤藥「甲苯磺酸索拉非尼片(0.2g)」均已獲中國國家藥品監督管理局頒發藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。此外,該附屬開發的蔥環類抗生素,屬廣譜抗腫瘤藥的「鹽酸多柔比星脂質體注射液(10ml:20mg)」同樣已獲國家藥品監督管理局批准通過仿製藥質量和療效一致性評價,為國內該品種首個通過一致性評價的產品。

恆指高見28,023,現造27,953,回升235點或近0.9%,成交額1,118億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account